Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Identification of Hepatic Lesions

This study has been completed.
Information provided by:
Bayer Identifier:
First received: March 27, 2006
Last updated: May 15, 2009
Last verified: May 2009
Patients with suspicion of primary or secondary hepatic malignancy in whom a radiological examination is needed in order to decide on the most appropriate treatment.

Condition Intervention Phase
Hepatic Neoplasms
Procedure: Resovist (BAY86-4884, SH U 555 A)
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: A Prospective, Multicenter, Phase III b Clinical Study to Evaluate the Effectiveness of Unenhanced and SH U 555A (Resovist) Enhanced MRI, Compared to Contrast-Enhanced Dual-Phase Spiral CT in Assessing the Correct Final Therapy-Deciding Diagnosis, in Patients With Primary or Secondary Hepatic Malignancies.

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • To assess the proportion of correct final, therapy deciding diagnosis based on unenhanced plus SH U 555 A enhanced MR imaging compared to contrast-enhanced dual-phase spiral CT.

Secondary Outcome Measures:
  • To assess the number, size , location and character of liver lesions.
  • To assess the diagnostic confidence of MRI and CT.
  • To assess the proportion of changed therapeutical decisions.
  • To assess sensitivity and specificity of MRI and CT.
  • To assess safety and tolerability of SH U 555 A administration.

Enrollment: 218
Study Start Date: April 2001
Study Completion Date: May 2003
Arms Assigned Interventions
Experimental: Arm 1 Procedure: Resovist (BAY86-4884, SH U 555 A)
Single bolus injection, followed by MRI

Detailed Description:

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.

Bayer Schering Pharma AG, Germany is the sponsor of the trial.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Present with suspicion of primary or secondary hepatic malignancy in whom a radiological examination is needed in order to decide on the most appropriate treatment. There should not be more than five liver lesions on type visualized on CT.

    The patient should be in a condition that allows subsequent treatment.

  2. Be willing and able to continue study participation following administration of SH U 555 A to ensure completion of all procedures and observations required by the trial protocol.
  3. Sign and date fully informed consent prior to entry into the study.

Exclusion Criteria:

  • Patients under 18 years of age.
  • Patients weighing less than 35 kg.
  • Patients who have received any investigational drug within the 30 days prior to entering this study.
  • Patients who have previously entered this study or any other study performed with SH U 555 A.
  • Women who are pregnant or who are of childbearing potential and have not had a negative urine pregnancy test immediately prior to the administration of SH U 555 A. The urine pregnancy test should be performed in accordance with the manufacturer's recommendations.
  • Lactating women.
  • Patients who have any contraindication to MRI examination.
  • Patients who have received any contrast material in the 24 hours prior to SH U 555 A injection, or who are scheduled to receive any contrast material within 24 hours afterwards. (In the case of any liver specific agent (e.g. MnDPDP, SPIOs, Gd-BOPTA) this will be extended to 14 days prior to the study).
  • Patients who have received Lipiodol contrast material at any time in the past or are scheduled to receive this during the study period.
  • Patients who are clinically unstable and whose clinical course during the observation period is unpredictable (e.g. due to previous surgery).
  • Patients scheduled for liver biopsy within 24 hours, or who had a biopsy within the 24 hours prior to planned SH U 555 A injection.
  • Patients who are scheduled for, or are likely to require, surgery within 24 hours after SH U 555 A injection.
  • Patients with a history of anaphylactoid or anaphylactic reaction to any allergen including drugs and contrast agents.
  • Patients with known hypersensitivity to any of the ingredients of SH U 555 A.
  • Patients with already clear op-indication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00307866

Bari, BA, Italy, 70124
Bologna, BO, Italy, 40100
Brescia, BS, Italy, 25123
Firenze, FI, Italy, 50100
Genova, GE, Italy, 16132
Milano, MI, Italy, 20132
Milano, MI, Italy, 20142
Milano, MI, Italy
Palermo, PA, Italy
Pisa, PI, Italy, 56126
Sassari, SS, Italy, 07100
Torino, TO, Italy, 10154
Trieste, TS, Italy, 34149
Verona, VE, Italy, 37134
Chieti, Italy, 66100
L'Aquila, Italy, 67100
Roma, Italy, 00144
Roma, Italy, 00161
Udine, Italy, 33100
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Therapeutic Area Head, Bayer Schering Pharma AG Identifier: NCT00307866     History of Changes
Other Study ID Numbers: 90956
Study First Received: March 27, 2006
Last Updated: May 15, 2009

Keywords provided by Bayer:
Known or suspected focal liver lesions detected by spiral CT

Additional relevant MeSH terms:
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases processed this record on May 25, 2017